Table 1.
Patient characteristics.
| Baseline characteristic | Trametinib (n = 24) | Chemotherapy (n = 20) |
|---|---|---|
| Age, years | ||
| Median (range) | 63 (40–78) | 61 (41–81) |
| Sex, n (%) | ||
| Female | 18 (75) | 11 (55) |
| Male | 6 (25) | 9 (45) |
| Hispanic, n (%) | ||
| Yes | 3 (13) | 1 (5) |
| No | 20 (83) | 19 (95) |
| Unknown | 1 (4) | 0 (0) |
| Race, n (%) | ||
| White | 16 (67) | 15 (75) |
| Black | 5 (21) | 2 (10) |
| Asian | 2 (8) | 3 (15) |
| Unknown | 1 (4) | 0 (0) |
| Planned chemotherapy, n (%) | ||
| 5-FU + leucovorin | 7 (29) | 6 (30) |
| Capecitabine | 17 (71) | 14 (70) |
| Zubrod performance status | ||
| 0 | 8 (33) | 6 (30) |
| 1 | 16 (67) | 14 (70) |
| Primary site, n (%) | ||
| Gall bladder | 8 (33) | 6 (30) |
| Extrahepatic biliary system | 2 (8) | 2 (10) |
| Intrahepatic biliary system | 14 (58) | 12 (60) |
| Serum CA 19–9a, U/mL, n (%) | ||
| <37 | 6 (25) | 7 (35) |
| ≥37 | 17 (71) | 13 (65) |
| Median (range) | 1238 (44–36,911) | 260 (45–66,010) |
| Prior treatment for biliary cancer | ||
| Adjuvant therapy | 14 (58) | 8 (40) |
| Local therapy | 0 (0) | 0 (0) |
| Single-agent chemotherapy | 2 (8) | 2 (10) |
| Multiple-agent chemotherapy | 13 (54) | 12 (60) |
| Surgery | 9 (38) | 5 (25) |
FU, fluorouracil.
a
One patient missing baseline serum CA 19–9.